

PHARMION CORP  
Form 8-K  
June 04, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
Date of Report (Date of earliest event reported) June 4, 2007  
Pharmion Corporation**

(Exact name of registrant as specified in its charter)

**Delaware**

**000-50447**

**84-1521333**

(State or other jurisdiction  
of incorporation)

(Commission File  
Number)

(IRS Employer  
Identification No.)

**2525 28<sup>th</sup> Street, Boulder, Colorado**

**80301**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code **720-564-9100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On June 4, 2007, Pharmion Corporation (the Company) announced that the French regulatory authority has granted an Autorisation Temporaire d Utilisation (ATU), or Temporary Authorization for Use, for Thalidomide (thalidomide) for the treatment of untreated multiple myeloma.

Also on June 4, 2007, the Company announced the final results of a Phase III study on Thalidomide (thalidomide) in elderly multiple myeloma patients.

The press releases are filed as Exhibits 99.1 and 99.2 to this Form 8-K and are incorporated herein by reference in its entirety.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

- 99.1 Press Release issued by Pharmion Corporation on June 4, 2007 announcing the granting of Temporary Authorization for Use for Thalidomide (thalidomide) for the treatment of untreated multiple myeloma.
- 99.2 Press Release issued by Pharmion Corporation on June 4, 2007 announcing Phase III Clinical Data on Thalidomide in Multiple Myeloma.

-2-

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PHARMION CORPORATION**

Date: June 4, 2007

By: **/s/ Steven N. Dupont**

Name: Steven N. Dupont

Title: Vice President and General Counsel

-3-

---

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued by Pharmion Corporation on June 4, 2007 announcing the granting of Temporary Authorization for Use for Thalidomide (thalidomide) for the treatment of untreated multiple myeloma.
99.2	Press Release issued by Pharmion Corporation on June 4, 2007 announcing Phase III Clinical Data on Thalidomide in Multiple Myeloma.